Mingqing Cai
mingqingcai.bsky.social
Scientist in Pharma/Biotech for 15 years; therapeutic antibodies and other fancy modalities; cytokines and inflammation; cancer, autoimmune, and Alzheimer's disease.
👤 Joined on 20 August 2024
334
Followers
592
Following
179
Total Posts
📜 Kullanıcı Geçmişi
- 20 Ağu 2024, 15:01
🎉 Bluesky'e katıldı - İlk kullanıcı adı:
@mingqingcai.bsky.social
🚫 Blokladığı Kullanıcılar
❤️ Beğendiği Gönderiler
In everything, not just Healthcare...
Show Post
#bioGUNE_News | 🗣️ #CICbioGUNE @brtaeus.bsky.social receives ERC Proof of Concept funding to develop bi-specific antibodies to transform cancer immunotherapy 🔬 BiParatopic project led by Jesús Jiménez-Barbero & June Ereño-Orbea #Ikerbasque 🔗 ow.ly/OCcU50UK2xP
Show Post
#THAR Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology https://www.stocktitan.net/news/THAR/tharimmune-announces-positive-target-engagement-with-novel-2j1duq25aqtd.html
Show Post
AI's promise as... - Critical complexity-mgmt tool - Vital integrator of ever-larger datasets available via improved meas tech incl digital/wearables - Personalization machine ...manifesting as key theme across many health domains incl nutrition, geromedicine, pharma R&D/clin dev, wellness; Pubs tk
Show Post
We have gotten some really good responses to science questions from platform.futurehouse.org already. Both from "Crow" (short answers) and "Falcon" (deep research). It looks like this is state of the art right now!
Show Post